What is the next catalyst for Intellia Therapeutics (NTLA)?

The next dated event is Phase 3 enrollment complete (MAGNITUDE-2) for Nex-z, expected H2 2026, as stated by the company. Also ahead: the FDA decision on Lonvo-z, on Mar 10, 2027.

How long will Intellia Therapeutics' cash last?

Intellia Therapeutics has said its cash will fund operations into 2028 (guidance as of November 5, 2026). It reported $615 million in cash as of September 30, 2026.

NTLAIntellia Therapeutics, Inc.

⚡

Intellia Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates - GlobeNewswire

GlobeNewswire · Nov 5, 1:00 PM

⚡

Intellia concludes Phase III ATTRv-PN study enrolment - Yahoo Finance

Yahoo Finance · Nov 5, 11:38 AM

⚡

Intellia Therapeutics Completes Enrollment in Phase 3 - GlobeNewswire

GlobeNewswire · Nov 4, 1:00 PM

Market reactionShares fell 11% on Nov 5.

IntactLast material event Sep 8, 2026 · Updated Oct 25, 2026

FDA accepted Intellia's BLA for lonvo-z in hereditary angioedema with Priority Review and a March 10, 2027 decision date; both nex-z Phase 3 trials resumed enrollment after FDA lifted its clinical holds

Intellia is a clinical-stage company developing one-time CRISPR gene-editing treatments; its lead, lonvo-z for hereditary angioedema, is under FDA review, and none of its products is approved.

Intellia's case rests on lonvo-z, a one-time CRISPR treatment for hereditary angioedema that cut attacks by 87% versus placebo in the Phase 3 HAELO trial. FDA set a March 10, 2027 decision date under Priority Review, and Intellia plans a U.S. launch in the first half of 2027 if approved. Nex-z, its ATTR amyloidosis treatment with Regeneron, resumed Phase 3 enrollment after a 2025 clinical hold over severe liver enzyme rises in a patient who later died. Cash of $628.4 million should fund operations at least into 2028.

Thesis checklist

1 risk needs attention

Select a row for evidence

What must be trueStateNext proof

FDA approves lonvo-zAwaiting evidenceFDA decision (March 10, 2027).Next: FDA decision (March 10, 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Lonvo-z launches in the first half of 2027Awaiting evidenceLaunch after approval (first half of 2027).Next: Launch after approval (first half of 2027).

Why it is in this state

The evidence, what would weaken it and the source filing

Nex-z Phase 3 trials enroll with liver risk controlledAt riskMAGNITUDE-2 enrollment completion (second half of 2026).Next: MAGNITUDE-2 enrollment completion (second half of 2026).

Why it is in this state

The evidence, what would weaken it and the source filing

Cash and debt fund the launchSupportedQ3 cash balance.Next: Q3 cash balance.

Why it is in this state

The evidence, what would weaken it and the source filing

Next decision point

FDA decision on lonvo-z

Tests: FDA approves lonvo-z

March 10, 2027

Does FDA approve lonvo-z on time with a broad HAE label?

Strong, inconclusive and weak outcomes

What to look for in the result and how each would move the checklist

Questions to investigate

History

Price and material events

Select an event marker to read the update below. Marker colors show Thesis status.

IntactCurrentRegulatory

-4.2%Sep 8, 2026

FDA accepted Intellia's BLA for lonvo-z in hereditary angioedema with Priority Review and a March 10, 2027 decision date; both nex-z Phase 3 trials resumed enrollment after FDA lifted its clinical holds

ChallengedFinancial

+0.5%Sep 4, 2026

lonvo-z's clean Phase 3 win drives the near-term BLA, while nex-z's liver safety determines whether the ATTR franchise succeeds

ChallengedRegulatory

+23.2%Jun 15, 2026

Intellia's lonvo-z BLA tests whether a one-time CRISPR HAE therapy can win market share against entrenched prophylaxis standards; nex-z safety holds the second key

ChallengedClinical

-42.2%Oct 27, 2025

MAGNITUDE/MAGNITUDE-2 trial pause for safety signal

About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.

Pipeline

Hereditary angioedema

lonvo-z · 1 upcoming · 4 completed

PDUFA Decision

March 10, 2027

ATTR with polyneuropathy

nex-z · 2 upcoming

Phase 3 Enrollment: CompletionMAGNITUDE-2

H2 2026

BLA Submission

TBD

ATTR amyloidosis with cardiomyopathy

nex-z · 1 upcoming

Phase 3 Enrollment: CompletionMAGNITUDE

TBD

ATTR cardiomyopathy· ATTR polyneuropathy

nex-z · 1 completed

Phase 1 Data: Long-term

Reported May 19, 2025

ATTR cardiomyopathy

nex-z · 1 completed

RMAT Designation

Reported May 8, 2025

Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.

Quick answers

Is the Intellia Therapeutics (NTLA) investment thesis intact?: Yes. Readouts currently rates the Intellia Therapeutics Thesis Intact. FDA accepted Intellia's BLA for lonvo-z in hereditary angioedema with Priority Review and a March 10, 2027 decision date; both nex-z Phase 3 trials resumed enrollment after FDA lifted its clinical holds.
What is the next catalyst for Intellia Therapeutics (NTLA)?: The next dated event is Phase 3 enrollment complete (MAGNITUDE-2) for Nex-z, expected H2 2026, as stated by the company. Also ahead: the FDA decision on Lonvo-z, on Mar 10, 2027.
How long will Intellia Therapeutics' cash last?: Intellia Therapeutics has said its cash will fund operations into 2028 (guidance as of November 5, 2026). It reported $615 million in cash as of September 30, 2026.

Other companies we cover in these diseases

Hereditary angioedema: Ionis Pharmaceuticals (IONS)

Drug pages: Lonvoguran ziclumeran (NTLA-2002)
Disease areas: Neuromuscular diseases, Obesity, diabetes and heart disease, Rare genetic and metabolic diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes

Competitive landscape

6 peers tracked

Financial snapshot

Dates and calculation details

Cash: Market-data provider estimate; measurement period unavailable.

Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.

Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.

Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.

Runway: No underlying guidance available.